Candel Therapeutics Cash Flow Statement Analysis
Values in millions USD
| Breakdown | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Period ending | Sep 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
| Operating Activities | ||||||||
| Net Income | -99.14 | -38.18 | -55.18 | -37.94 | -18.79 | -36.12 | -17.68 | -8.24 |
| Depreciation & Amortization | 0.65 | 0.85 | 0.99 | 0.96 | 0.78 | 0.23 | 0.09 | 0.04 |
| Deferred Income Tax | - | 0.00 | 0.00 | 0.00 | 0.00 | 11.51 | 0.00 | 0.00 |
| Stock Based Compensation | 8.26 | 3.82 | 5.31 | 3.09 | 2.31 | 2.96 | 2.11 | 0.40 |
| Change in Working Capital | 2.31 | 2.19 | 0.35 | -0.53 | 0.07 | -0.88 | 1.77 | 0.51 |
| Change in Accounts Payable | 1.54 | 0.80 | -0.19 | 0.05 | -1.21 | 0.67 | 0.29 | 0.01 |
| Change in Other Working Capital | 0.84 | 1.39 | 0.53 | -0.38 | 0.07 | -1.55 | 1.61 | 0.50 |
| Other Operating Activities | 18.06 | -6.98 | 21.51 | -0.62 | 0.59 | 0.08 | 4.64 | 2.11 |
| Net Cash from Operating Activities | -68.91 | -38.31 | -27.02 | -34.24 | -31.42 | -22.22 | -9.07 | -5.18 |
| Investing Activities | ||||||||
| Capital Expenditures | -1.29 | -0.59 | -0.02 | -0.46 | -1.30 | -1.84 | -1.48 | -0.16 |
| Acquisitions | - | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.85 |
| Purchases of Investments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.93 | -39.11 |
| Sales/Maturities of Investments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.94 | 4.37 |
| Other Investing Activities | - | 0.00 | 0.00 | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash from Investing Activities | -1.29 | -0.56 | -0.02 | -0.28 | -1.30 | -1.84 | 38.46 | -35.74 |
| Financing Activities | ||||||||
| Debt Repayment | - | 36.21 | -9.17 | 0.00 | 19.91 | 0.00 | 0.46 | -0.52 |
| Common Stock Issued | 142.61 | 19.89 | 101.76 | 0.00 | 0.00 | 71.34 | 0.03 | 0.00 |
| Common Stock Repurchased | - | 0.00 | 0.00 | -0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities | - | 0.00 | 1.69 | -0.12 | 0.06 | 0.47 | 0.03 | 22.50 |
| Net Cash from Financing Activities | 186.50 | 56.10 | 94.28 | -0.12 | 19.97 | 71.80 | 0.49 | 21.98 |
| Summary | ||||||||
| Net Change in Cash | 116.30 | 17.23 | 67.24 | -34.65 | -12.74 | 47.75 | 29.87 | -18.94 |
| Cash at Beginning of Period | 87.23 | 102.92 | 35.68 | 70.32 | 83.07 | 35.32 | 5.45 | 24.38 |
| Cash at End of Period | 203.53 | 120.15 | 102.92 | 35.68 | 70.32 | 83.07 | 35.32 | 5.45 |
| Free Cash Flow | -70.20 | -38.90 | -27.04 | -34.70 | -32.72 | -24.05 | -10.55 | -5.34 |
| Supplemental Disclosures | ||||||||
| Interest Paid | 4.37 | 1.28 | 1.80 | 2.15 | 1.15 | - | - | - |
| Income Taxes Paid | - | - | - | - | 0.18 | 0.03 | 0.09 | - |
Source: Company financial statements from annual and quarterly filings. Data as of Sep 30, 2026. Data sources and methodology
